Rebecca Burke
Psychiatric/Mental Health, Child & Family · Little Rock, ARNPI 1982031514
Payments from drug & device makers
Across 545 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$920
- Teva Pharmaceuticals USA, Inc.$803
- plus $5K from 21 others
What the payments were for
- Food & beverage$11,703100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 56 | $1,735 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $1,178 |
| AbbVie | 72 | $1,142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $1,007 |
| Johnson & Johnson | 32 | $920 |
| Teva Pharmaceuticals USA, Inc. | 42 | $803 |
| Axsome Therapeutics, Inc. | 30 | $634 |
| Neurocrine Biosciences, Inc. | 21 | $574 |
| Supernus Pharmaceuticals, Inc. | 20 | $550 |
| Vanda Pharmaceuticals Inc. | 29 | $526 |
| Lundbeck LLC | 24 | $455 |
| Alkermes, Inc. | 18 | $353 |
| Almatica Pharma LLC | 15 | $347 |
| Tris Pharma Inc | 12 | $286 |
| Ironshore Pharmaceuticals Inc. | 15 | $285 |
| Sunovion Pharmaceuticals Inc. | 11 | $180 |
| Idorsia Pharmaceuticals US Inc | 9 | $145 |
| Corium, LLC | 7 | $132 |
| Avanir Pharmaceuticals, Inc. | 6 | $124 |
| Noven Therapeutics, LLC | 4 | $88 |
| Bausch Health US, LLC | 4 | $79 |
| Eisai Inc. | 3 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Biogen | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$311
- SPRAVATO$242
- REXULTI$211
- AUSTEDO$118
- ABILIFY ASIMTUFII$104
How this compares
Too few psychiatric/mental health, child & family providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $114,666 |
| RexultiBrexpiprazole | 51 | $87,176 |
| VraylarCariprazine Hcl | 30 | $44,858 |
| BelsomraSuvorexant | 59 | $32,434 |
| ZyprexaOlanzapine | 13 | $27,316 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 749 | $23,504 |
| CaplytaLumateperone Tosylate | 12 | $22,948 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 187 | $14,783 |
| Chlorpromazine Hcl | 63 | $12,849 |
| Bupropion XlBupropion Hcl | 542 | $12,518 |
| Ziprasidone Hcl | 156 | $12,440 |
| Lurasidone Hcl | 97 | $11,450 |
| Quetiapine Fumarate | 484 | $11,236 |
| Clonazepam | 1,170 | $10,366 |
| Atomoxetine Hcl | 55 | $10,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $803 | $114,66611 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,735 | $87,17651 claims |
| AbbVieVraylar, Saphris | $1,142 | $52,35743 claims |
| MerckBelsomra | $15 | $32,43459 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,178 | $22,94812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $1,007 | $18,43637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, child & family providers in Arkansason file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, child & family in Little Rock
- Nancy StamFort Smith$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.